{"id":378,"date":"2020-07-18T10:58:26","date_gmt":"2020-07-18T10:58:26","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=378"},"modified":"2020-07-18T10:58:26","modified_gmt":"2020-07-18T10:58:26","slug":"17-july-2020-tocilizumab-clinical-improvement-by-days-7-and-14-were-44-3-39-88-and-73-9-65-88","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/17-july-2020-tocilizumab-clinical-improvement-by-days-7-and-14-were-44-3-39-88-and-73-9-65-88\/","title":{"rendered":"(17 July 2020) Tocilizumab- clinical improvement by days 7 and 14 were 44.3% (39\/88) and 73.9% (65\/88)"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"citation__title\">Tocilizumab for the treatment of adult patients with severe COVID\u201019 pneumonia: a single\u2010center cohort study<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1002\/jmv.26308<\/p>\n<p class=\"\">88 consecutive patients with COVID-19 pneumonia that received at least one dose of intravenous TCZ&nbsp; were retrospectively analyzed. Clinical status from day 0 (first TCZ dose) through day 14 was assessed by a six-point ordinal scale. The primary outcome was clinical improvement (hospital discharge and\/or a decrease of &gt;\/=2 points on the six-point scale) by day 7. Rates of clinical improvement by days 7 and 14 were 44.3% (39\/88) and 73.9% (65\/88). Previous or concomitant receipt of subcutaneous interferon-beta (adjusted odds ratio [aOR]: 0.23; 95% confidence interval [CI]: 0.06 &#8211; 0.94; P-value = 0.041) and serum lactate dehydrogenase &gt;450 U\/L at day 0 (aOR: 0.25; 95% CI: 0.06 &#8211; 0.99; P-value = 0.048) were negatively associated with clinical improvement by day 7. All-cause mortality was 6.8% (6\/88). Body temperature and respiratory and cardiac rates significantly decreased by day 1 compared to day 0. Lymphocyte count and pulse oximetry oxygen saturation\/FiO2 ratio increased by days 3 and 5, whereas C-reactive protein levels dropped by day 2. There were no TCZ-attributable adverse events.&nbsp; In this observational single-center study, TCZ appeared to be useful and safe as immunomodulatory therapy for severe COVID-19 pneumonia.&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tocilizumab for the treatment of adult patients with severe COVID\u201019 pneumonia: a single\u2010center cohort study https:\/\/doi.org\/10.1002\/jmv.26308 88 consecutive patients with COVID-19 pneumonia that received at least one dose of intravenous TCZ&nbsp; were retrospectively analyzed. Clinical status from day 0 (first&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/17-july-2020-tocilizumab-clinical-improvement-by-days-7-and-14-were-44-3-39-88-and-73-9-65-88\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(17 July 2020) Tocilizumab- clinical improvement by days 7 and 14 were 44.3% (39\/88) and 73.9% (65\/88)&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/378"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=378"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/378\/revisions"}],"predecessor-version":[{"id":379,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/378\/revisions\/379"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}